Evidence map›Paper›PMID 34201241›Full record

ArticleCancers2021

Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma.

Julie A Webster, Alain Wuethrich, Karthik B Shanmugasundaram, Renee S Richards, Wioleta M Zelek, Alok K Shah, Louisa G Gordon, Bradley J Kendall, Gunter Hartel, B Paul Morgan and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Julie A WebsterQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Alain WuethrichCentre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia.ORCID 0000-0001-9569-0478
Karthik B ShanmugasundaramCentre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia.
Renee S RichardsQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.ORCID 0000-0002-8911-8966
Wioleta M ZelekDivision of Infection and Immunity, Cardiff University, Heath Park, Cardiff CF10 3AX, UK.
Alok K ShahQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Louisa G GordonQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.ORCID 0000-0002-3159-4249
Bradley J KendallQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Gunter HartelQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
B Paul MorganDivision of Infection and Immunity, Cardiff University, Heath Park, Cardiff CF10 3AX, UK.ORCID 0000-0003-4075-7676
Matt TrauCentre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane City, QLD 4072, Australia.ORCID 0000-0001-5516-1280
Michelle M HillQIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.ORCID 0000-0003-1134-0951
QIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUCardiff University · GB

Funding

Molecular epidemiology of Barretts esophagus and cancerR01CA001833 · NCI · QUEENSLAND INSTITUTE OF MEDICAL RESEARCH · PI WHITEMAN, DAVID C · 2002 to 2006
$1.3M
Australian Research Council DP210103151HCRW_ HF-19-1595National Breast Cancer Foundation of Australia CG-12-07National Foundation for Medical Research and Innovation n/aNational Health and Medical Research Council APP1173669NCI NIH HHS 5 RO1 CA 001833-02
6 · The paper itself

Abstract

The current endoscopy and biopsy diagnosis of esophageal adenocarcinoma (EAC) and its premalignant condition Barrett's esophagus (BE) is not cost-effective. To enable EAC screening and patient triaging for endoscopy, we developed a microfluidic lectin immunoassay, the EndoScreen Chip, which allows sensitive multiplex serum biomarker measurements. Here, we report the proof-of-concept deployment for the EAC biomarker Jacalin lectin binding complement C9 (JAC-C9), which we previously discovered and validated by mass spectrometry. A monoclonal C9 antibody (m26 3C9) was generated and validated in microplate ELISA, and then deployed for JAC-C9 measurement on EndoScreen Chip. Cohort evaluation (

Indexed as

Barrett’s esophagusbiomarkercomplement componentglycoproteinlectinliquid biopsyscreeningSERSsurface-enhanced Raman spectroscopysurveillance

Identifiers

PMID34201241
PMCPMC8229863
OpenAlexW3167345296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.